[HTML] nejm.org

[HTML][HTML] Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase

HM El Sahly, LR Baden, B Essink… - … England Journal of …, 2021 - Mass Medical Soc
Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease …
被引用次数：534 相关文章

[引用][C] Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

HM El Sahly, LR Baden, B Essink… - The New England …, 2021 - scholarship.miami.edu
The mRNA-1273 vaccine was approved for emergency use in December 2020; trial
participants who received placebo were informed of the results and offered vaccination. At …
[HTML] nih.gov

[HTML][HTML] Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

HM El Sahly, LR Baden, B Essink… - The New England … - ncbi.nlm.nih.gov
Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease …

Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase.

HM El-Sahly, LR Baden, B Essink, S Doblecki-Lewis… - 2021 - cabidigitallibrary.org
BACKGROUND: At interim analysis in a phase 3, observer-blinded, placebo-controlled
clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus …

Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase

RJ Whitley, A Babiker, LA Cooper… - … England Journal of …, 2021 - pure.johnshopkins.edu
BACKGROUND At interim analysis in a phase 3, observer-blinded, placebo-controlled
clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus …

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

HM El Sahly, LR Baden, B Essink… - New England Journal …, 2021 - cir.nii.ac.jp
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.

HM El Sahly, LR Baden, B Essink… - The New England …, 2021 - europepmc.org
Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease …
[PDF] henryford.com

[PDF][PDF] Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

HM El Sahly, LR Baden, B Essink, S Doblecki-Lewis… - scholarlycommons.henryford.com
BACKGROUND At interim analysis in a phase 3, observer-blinded, placebo-controlled
clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus …
[PDF] inskriptionen.de

[PDF][PDF] Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

HM El Sahly - inskriptionen.de
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase Page 1
Days since Randomization CumulativeIncidence(%) Placebo mRNA-1273 0 20 40 60 80 …

Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase

RJ Whitley, A Babiker, LA Cooper… - … England Journal of …, 2021 - jhu.pure.elsevier.com
BACKGROUND At interim analysis in a phase 3, observer-blinded, placebo-controlled
clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus …